Administrative claims may provide an understanding of the clinical and economic burden of novel coronavirus disease 2019 (COVID-19). However, their limited sensitivity in identifying conditions, such as sepsis,1 suggests the need to assess whether billing codes reliably capture COVID-19 discharges.
A new diagnosis code for COVID-19 (International Statistical Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] code U07.1) was introduced on April 1, 2020, to facilitate billing and case monitoring.2 For discharges prior to April 1, 2020, the Centers for Disease Control and Prevention advised coding for the clinical syndrome (eg, pneumonia) and “other coronavirus as the cause of diseases classified elsewhere” (ICD-10-CM code B97.29).3
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: September 28, 2020.
Corresponding Author: Ning Rosenthal, MD, PhD, MPH, Premier Applied Sciences, Premier Healthcare Solutions Inc, 13034 Ballantyne Corporate Pl, Charlotte, NC 28277 (firstname.lastname@example.org).
Author Contributions: Ms Warner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kadri, Gundrum, Cao, Rosenthal.
Acquisition, analysis, or interpretation of data: Kadri, Gundrum, Warner, Babiker, Klompas, Rosenthal.
Drafting of the manuscript: Kadri, Warner, Rosenthal.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Gundrum, Warner, Cao, Rosenthal.
Obtained funding: Kadri, Rosenthal.
Administrative, technical, or material support: Warner, Rosenthal.
Supervision: Kadri, Rosenthal.
Conflict of Interest Disclosures: Mr Gundrum, Dr Cao, and Dr Rosenthal are employees and shareholders of Premier Healthcare Solutions Inc. Dr Klompas reported receiving grants from the Centers for Disease Control and Prevention and receiving grants and personal fees from UpToDate. No other disclosures were reported.
Funding/Support: This work was supported by Premier Healthcare Solutions Inc and the Intramural Research Program of the National Institutes of Health Clinical Center.
Role of the Funder/Sponsor: The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the National Institutes of Health.
Additional Contributions: We thank John P. Dekker, MD, PhD, National Institute of Allergy and Infectious Diseases, for his insightful feedback on laboratory testing for SARS-CoV-2. Dr Dekker did not receive financial compensation for his contribution.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.